SCPS (Scopus BioPharma) Retained Earnings: $-58.13 Mil (As of Jun. 2023)


What is Scopus BioPharma Retained Earnings?

Scopus BioPharma SCPS Retained Earnings is $-58.13 Mil as of Jun. 2023.

Retained earnings is the accumulated portion of net income that is not distributed to shareholders. Scopus BioPharma's retained earnings for the quarter that ended in Jun. 2023 was $-58.13 Mil.

Scopus BioPharma's quarterly retained earnings declined from Dec. 2022 ($-53.07 Mil) to Mar. 2023 ($-55.52 Mil) and declined from Mar. 2023 ($-55.52 Mil) to Jun. 2023 ($-58.13 Mil).

Scopus BioPharma's annual retained earnings declined from Dec. 2020 ($-14.50 Mil) to Dec. 2021 ($-41.46 Mil) and declined from Dec. 2021 ($-41.46 Mil) to Dec. 2022 ($-53.07 Mil).

Scopus BioPharma  (OTCPK:SCPS) Retained Earnings Explanation

Historically profitable companies sometimes have negative retained earnings. This is because they have cumulatively paid out more to shareholders than they reported in profits.

For example, in 2011, Microsoft had negative retained earnings. This does not mean the company lost more money than it made over the years. It just means it paid out more money than it earned.

If a company has negative retained earnings, investors should check the 10-year financial results. They should not assume that negative retained earnings prove a company has generally lost money in the past.

Of course, many companies with negative retained earnings have indeed lost money in the past.

Retained Earnings: Warren Buffett's Secret.

One of the most important indicators of durable competitive advantage. Net earnings can be paid out as dividends, used to buy back shares or retained for growth.

If the company loses more than it has accumulated, retained earnings is negative.

If a company isn't adding to its retained earnings, it isn't growing its net worth.

Rate of growth of retained earnings is good indicator whether it's benefiting from a competitive advantage.

Microsoft is negative because it chose to buyback stock and pay dividends.

The more earnings retained, the faster it grows and increases growth rate for future earnings.

Scopus BioPharma Retained Earnings Historical Data

* Premium members only.

The historical data trend for Scopus BioPharma's Retained Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Scopus BioPharma Retained Earnings Chart

Scopus BioPharma Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Retained Earnings
Get a 7-Day Free Trial -0.95 -3.64 -14.50 -41.46 -53.07

Scopus BioPharma Quarterly Data
Jun18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23
Retained Earnings Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -49.44 -51.33 -53.07 -55.52 -58.13

Scopus BioPharma Retained Earnings Calculation

Retained Earnings is the accumulated portion of net income that is not distributed to shareholders. Because the net income was not distributed to shareholders, shareholders' equity is increased by the same amount.

Of course, if a company loses, it is called retained losses, or accumulated losses.

Frequently Asked Questions Learn more about Retained Earnings →
What does a Retained Earnings of $-58.13 Mil mean?
Scopus BioPharma (SCPS) has a Retained Earnings of $-58.13 Mil as of Jun. 2023. Retained earnings is the amount of net income not issued to shareholders. View historical data on Scopus BioPharma and its competitors.
Is Scopus BioPharma's Retained Earnings too high?
Scopus BioPharma's current Retained Earnings is $-58.13 Mil.
How does Scopus BioPharma's Retained Earnings compare to AMPE and DRMA?
Scopus BioPharma's Retained Earnings of $-58.13 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Retained Earnings for a Biotechnology company?
A good Retained Earnings depends on the Biotechnology industry context. However, Retained Earnings should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Retained Earnings mean?
A high Retained Earnings can signal that a stock is expensive relative to its fundamentals. Retained earnings is the amount of net income not issued to shareholders. View historical data on Scopus BioPharma and its competitors. Scopus BioPharma's current Retained Earnings is $-58.13 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Scopus BioPharma stock overvalued right now?
Scopus BioPharma (SCPS) has a current Retained Earnings of $-58.13 Mil. The current Retained Earnings is $-58.13 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Retained Earnings calculated?
Retained Earnings is calculated from a company's financial statements. For Scopus BioPharma (SCPS), the current Retained Earnings is $-58.13 Mil as of Jun. 2023. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Scopus BioPharma Business Description

Address 420 Lexington Avenue, Suite 300, New York, NY, USA, 10170
Scopus BioPharma Inc a biotechnology company focused on developing therapeutics targeting the endocannabinoid system. The endocannabinoid system is comprised of chemical compounds, or cannabinoids, that interact with cannabinoid receptors which are located throughout the body. Its product candidate comprises CO-sTiRNA, which is a STAT3 inhibitor gene therapy and MRI-1867.